NCT03996473View on ClinicalTrials.gov

Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases

PHASE1TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 6, 2020

Primary Completion Date

April 14, 2021

Study Completion Date

January 30, 2023

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Radium-223 dichloride (Xofigo, BAY 88-8223)

55 kBq/kg, intravenous (IV) injection, every 6 weeks for up to 6 administrations

DRUG

Pembrolizumab

200 mg, IV infusion, every 3 weeks for a maximum of up to 35 administrations

Trial Locations (6)

9000

UZ Gent, Ghent

28041

Hospital Universitario 12 de Octubre, Madrid

92069

Ccare San Marcos Cancer Center & Urology, San Marcos

1066 CX

Nederlands Kanker Instituut, Amsterdam

08035

Ciutat Sanitaria i Universitaria de la Vall d'Hebron, Barcelona

08036

Hospital Clínic i Provincial de Barcelona, Barcelona

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Bayer

INDUSTRY

NCT03996473 - Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases | Biotech Hunter | Biotech Hunter